Ras Al Khaimah Hospital: Reducing migraine attacks using calcitonin-linked inhibitors
The doctors of the Department of Neurology at Ras Al Khaimah Hospital were able to reduce the migraine attacks of its patients from 50 to 60% per month, using a new treatment with inhibitors (calcitonin-linked peptide) known as (CGRP), to reduce the frequency of headache attacks, as the treatment aims to reduce the number of Days of headache associated with migraine.
The executive director of Ras Al Khaimah Hospital, Dr. Reda Siddiqi, said that in the absence of a medicine intended to prevent migraines, doctors used to treat the disease with pain relievers, triptans and other antidepressants, epilepsy medicines and anti-hypertensives on a regular basis.
He explained, that migraines are diseases that are not diagnosed and treated adequately in most cases, and they negatively affect all aspects of patients' lives, especially the personal and professional aspects, as well as greatly affect the quality of life of patients who suffer from headaches about 15 days every month, What makes their life so difficult.
He added that the new treatment with inhibitors (calcitonin-linked peptide) is one of the promising drugs with great results that bring great benefits to the patient, which he can tolerate well, and that he can take it himself in the form of injections. Daily in the UAE.
Dr Swita Adatia, the specialist doctor and head of the neurology department at Ras Al Khaimah Hospital, said that treatment with calcitonin-linked peptide inhibitors heralds a new era of migraine treatments, giving hope to millions of patients suffering from this disease.
She explained that the hospital receives more than 100 patients a month who complain of headaches, and it has been found that 60% of them suffer from migraine, and the use of the new treatment with inhibitors (peptide linked to the calcitonin gene) has contributed to improving the quality of life of patients within a short period of time, as they are witnessing a significant decrease. On the number of headaches per month.
She also explained, "The new treatment is characterized by a rapid response and the emergence of its clinical benefits compared to the traditional preventive drugs, which we used to give to the patient in increasing doses to reach the appropriate dose and then wait for a period ranging between 3-6 months to see how effective it is, and this treatment is also effective for patients who did not show any Improvement in their condition when following previous treatments. "
She pointed out that migraine is one of the specific neurological diseases whose symptoms include frequent headaches ranging from moderate to severe on one side of the head, with a feeling of throbbing or pulsing at the site of pain, and it is often accompanied by nausea, vomiting, and severe sensitivity to light and noise.
A migraine attack can last for hours to days, and it may be so severe that it impedes the patient's ability to carry out his daily activities.
Follow our latest local and sports news, and the latest political and economic developments via Google news